NCT01012167 Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia Status COMPLETED Phase PHASE2
NCT01010776 A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone Status COMPLETED Phase PHASE4
NCT01010477 Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia Status COMPLETED Phase PHASE4
NCT01009060 Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia Status COMPLETED Phase PHASE2
NCT01009047 An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia Status COMPLETED Phase PHASE3
NCT01006551 Ziprasidone in Early Onset Schizophrenia Spectrum Disorders Status COMPLETED Phase PHASE2
NCT01003379 TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia Status COMPLETED Phase PHASE2
NCT01003132 Assessing the Effectiveness of Acceptance and Commitment Therapy for Distress Following Psychosis Status COMPLETED Phase NA
NCT00999895 A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients Status COMPLETED Phase N/A
NCT00999505 Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia Status UNKNOWN Phase PHASE3
NCT00998608 Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of Schizophrenia Status TERMINATED Phase PHASE4
NCT00996242 An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With Schizophrenia Status COMPLETED Phase NA
NCT00992407 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Status COMPLETED Phase PHASE4